6 min read

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

By Emergent CDMO on Sep 14, 2021 9:09:49 AM

  • Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021

GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE)-- Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent’s integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence’s COVID-19 messenger RNA (mRNA) vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief.

Topics: COVID-19 news
4 min read

Emergent BioSolutions on Track with Respect to COVID-19 Contractual Commitments

By Emergent CDMO on Apr 4, 2021 11:45:00 PM

EMERGENT BIOSOLUTIONS ON TRACK WITH RESPECT TO COVID-19 CONTRACTUAL COMMITMENTS; RECEIVES MODIFIED TASK ORDER FROM THE U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES TO SUPPORT THE OPPORTUNITY FOR FURTHER EXPANSION OF MANUFACTURING CAPACITY FOR JOHNSON & JOHNSON’S COVID-19 VACCINE

  • HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipment
  • Reaffirms 2021 financial guidance

GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).

Topics: COVID-19 news

Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing

By Catherine Hanley on Feb 12, 2021 2:00:00 PM

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing services for their investigational mRNA vaccine candidate (PTX-COVID19-B) at its facility in Winnipeg, Manitoba, Canada. This is Emergent's 8th COVID-19 CDMO collaboration, and first outside of the U.S. in Canada.

Topics: COVID-19 news
6 min read

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

By Catherine Hanley on Jan 25, 2021 9:23:46 AM

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021  Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm.” Emergent will provide access to manufacturing capacity reserved for and provided by the U.S. government under Humanigen’s Cooperative Research and Development Agreement (CRADA) with the Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for emergency use authorization (EUA) in the first quarter of 2021.

Topics: COVID-19 news

Bloomberg: The Way Ahead

By Catherine Hanley on Oct 1, 2020 9:00:00 AM

Emergent BioSolutions, a Wells Fargo Corporate & Investment Banking customer since 2011, helps governments respond to health emergencies before they happen. Eight years ago, they were planning for a crisis like Covid-19. America will need hundreds of millions of doses of a vaccine. Emergent is manufacturing them now, before they've been approved for use, so they'll be ready if they measure up. 

Topics: COVID-19
1 min read

All Hands on Deck for Fill/Finish of Vaccines and Therapeutics

By Catherine Hanley on Aug 31, 2020 4:58:00 PM

“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and effective medical countermeasures for public health. BARDA has been an excellent partner, across all levels from leadership to the project and technical teams with whom we work closely. As partners on a team, we work collaboratively to monitor, evaluate, and progress projects and help remove barriers that slow down the directive of Operation Warp Speed.”

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions contributed to an editorial in the August issue of Pharmaceutical Technology on the pivotal role outsourcing partners are having in the rapid development and production of COVID-19 vaccine candidates. 

Read the full article here

Topics: COVID-19
1 min read

Preparing Pandemic Vaccine Capacity

By Catherine Hanley on Aug 18, 2020 9:59:52 AM

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently contributed to an editorial in Pharmtech.com discussing the importance of collaboration between innovators, manufacturing partners, and the entire supply chain when preparing for rapid scale-up of COVID-19 vaccine candidates. 

Topics: COVID-19

COVID-19: 'Pandemic-ready' set-up placing Emergent apart in CDMO Space

By Catherine Hanley on Jul 29, 2020 9:00:00 AM

In a recent article with BioProcess International, Syed T. Husain, senior vice president & CDMO business unit head at Emergent BioSolutions, discusses the critical role Emergent has in supporting the development & manufacturing of COVID-19 vaccine candidates. 

Topics: COVID-19
6 min read

Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate

By Catherine Hanley on Jul 27, 2020 8:56:21 AM

  • Emergent will provide contract development and manufacturing services beginning in 2020 to produce drug substance at large scale for commercial supply
  • Agreement is valued at approximately $174 million through 2021 and brings the total AstraZeneca commitment to $261 million
  • Parties may enter into additional commercial manufacturing commitments as the candidate progresses over three years through Emergent’s flexible capacity deployment model

GAITHERSBURG, Md., July 27, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222. The agreement is valued at approximately $174 million through 2021 and follows an $87 million contract in June for development services, performance and process qualification, raw materials and an initial capacity reservation.

Topics: COVID-19 news
14 min read

EMERGENT IN THE NEWS: COVID-19 General Coverage

By Catherine Hanley on Jul 7, 2020 3:00:00 PM

Read the latest news coverage of Emergent's insights and involvement in the fight against COVID-19.
Last Updated: Thursday, November 12, 2020

Topics: COVID-19

Featured